Search Results - "Cullen, M H"

Management of febrile neutropenia: ESMO Clinical Practice Guidelines by de Naurois, J., Novitzky-Basso, I., Gill, M. J., Marti, F. Marti, Cullen, M. H., Roila, F.

Get full text

A phase II trial of TIP (paclitaxel, ifosfamide and cisplatin) given as second-line (post-BEP) salvage chemotherapy for patients with metastatic germ cell cancer: a medical research council trial by MEAD, G. M, CULLEN, M. H, HUDDART, R, HARPER, P, RUSTIN, G. J. S, COOK, P. A, STENNING, S. P, MASON, M

“…This phase II trial describes the use of TIP chemotherapy (paclitaxel, ifosfamide and cisplatin) as salvage for patients with metastatic germ cell cancer (GCC)…”
Get full text

Mitomycin, Ifosfamide, and Cisplatin in Unresectable Non–Small-Cell Lung Cancer: Effects on Survival and Quality of Life by CULLEN, M. H, BILLINGHAM, L. J, TRASK, C, BESSELL, E, CONNOLLY, C. K, TOBIAS, J, SOUHAMI, R. L, WOODROFFE, C. M, CHETIYAWARDANA, A. D, GOWER, N. H, JOSHI, R, FERRY, D. R, RUDD, R. M, SPIRO, S. G, COOK, J. E

“…Chemotherapy for non-small-cell lung cancer (NSCLC) remains controversial. We describe the two largest reported, randomized, parallel trials designed to…”
Get full text

A randomized phase III trial comparing standard and high-dose pemetrexed as second-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer by Cullen, M. H., Zatloukal, P., Sörenson, S., Novello, S., Fischer, J. R., Joy, A. A., Zereu, M., Peterson, P., Visseren-Grul, C. M., Iscoe, N.

“…Background: This phase III randomized trial compared pemetrexed 500 mg/m2 (P500) with pemetrexed 900 mg/m2 (P900) to determine whether higher dosing benefits…”
Get full text

North Atlantic influence on Tigris–Euphrates streamflow by Cullen, Heidi M., deMenocal, Peter B.

“…Changes in streamflow of the Tigris and the Euphrates Rivers are shown to be associated with the North Atlantic Oscillation (NAO), a large‐scale mode of…”
Get full text

Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report by Cullen, M H, Stenning, S P, Parkinson, M C, Fossa, S D, Kaye, S B, Horwich, A H, Harland, S J, Williams, M V, Jakes, R

“…This United Kingdom Medical Research Council (UK-MRC) study prospectively evaluated efficacy and long-term toxicity of adjuvant chemotherapy in high-risk stage…”
Get more information

Initial dose intensity has limited impact on the outcome of ABVD chemotherapy for advanced Hodgkin lymphoma (HL): data from UKLG LY09 (ISRCTN97144519) by Owadally, W.S., Sydes, M.R., Radford, J.A., Hancock, B.W., Cullen, M.H., Stenning, S.P., Johnson, P.W.M.

“…This analysis was undertaken to assess the relationship between the dose intensity (DI) of initial chemotherapy and outcome in a large cohort of patients with…”
Get full text

Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial by Horwich, A, Sleijfer, D T, Fosså, S D, Kaye, S B, Oliver, R T, Cullen, M H, Mead, G M, de Wit, R, de Mulder, P H, Dearnaley, D P, Cook, P A, Sylvester, R J, Stenning, S P

“…This prospective randomized multicenter trial was designed to evaluate the efficacy of carboplatin plus etoposide and bleomycin (CEB) versus cisplatin plus…”
Get more information

Adjuvant bleomycin, vincristine and cisplatin (BOP) for high-risk stage I non-seminomatous germ cell tumours: a prospective trial (MRC TE17) by DEARNALEY, D. P, FOSSA, S. D, COOK, P. A, STENNING, S. P, KAYE, S. B, CULLEN, M. H, HARLAND, S. J, SOKAL, M. P. J, GRAHAM, J. D, ROBERTS, J. T, MEAD, G. M, WILLIAMS, M. V

“…Adjuvant BEP (bleomycin, etoposide, cisplatin) is effective treatment for high-risk clinical stage I (HRCS1) non-seminomatous germ cell tumours (NSGCT), but…”
Get full text

Optimal Planning Target Volume for Stage I Testicular Seminoma: A Medical Research Council Randomized Trial by FOSSA, S. D, HORWICH, A, GROSCH, E. J, CHETIYAWARDANA, A. D, REED, N. S, WIDMER, B, RUSSELL, J. M, ROBERTS, J. T, CULLEN, M. H, HODSON, N. J, JONES, W. G, YOSEF, H, DUCHESNE, G. M, OWEN, J. R

“…PURPOSE: To compare relapse rates and toxicity associated with para-aortic (PA) strip or PA and ipsilateral iliac lymph node irradiation (dogleg [DL] field)…”
Get full text

A Medical Research Council randomized trial of single agent carboplatin versus etoposide and cisplatin for advanced metastatic seminoma by HORWICH, A, OLIVER, R. T. D, STENNING, S. P, WILKINSON, P. M, MEAD, G. M, HARLAND, S. J, CULLEN, M. H, ROBERTS, J. T, FOSSA, S. D, DEARNALEY, D. P, LALLEMAND, E

“…The UK Medical Research Council conducted this trial of carboplatin chemotherapy in advanced seminoma to compare single agent carboplatin with a standard…”
Get full text

Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours by FOSS, S. D, STENNING, S. P, MEAD, G. M, CULLEN, M. H, KAYE, S. B, RUSTIN, G. J. S, COOK, P. A, GERL, A, HORWICH, A, CLARK, P. I, WILKINSON, P. M, JONES, W. G, WILLIAMS, M. V, OLIVER, R. T, NEWLANDS, E. S

“…The aim of this study was to define prognostic parameters for survival in patients with malignant germ cell tumours progressing after platinum-based induction…”
Get full text

The benefits of chemotherapy in patient subgroups with unresectable non-small-cell lung cancer by Billingham, L. J., Cullen, M. H.

“…Summary Background: Cisplatin-based chemotherapy improves survival in advanced non-small-cell lung cancer. Using data from phase III trials of mitomycin,…”
Get full text

A phase II clinical trial of gemcitabine and split dose cisplatin in advanced non-small cell lung cancer in an outpatient setting by HUSSAIN, S. A, PALMER, D. H, CHETIYAWARDANA, A. D, CULLEN, M. H, SWINSON, D. E, RILEY, P, WILLS, A, BROWN, C, DRAYCOTT, C, EL-MODIR, A, PEAKE, D. R, REA, D. W

“…In response to increasing pressure on inpatient services and a meta-analysis indicating that cisplatin (C) is superior to carboplatin, we report a phase II…”
Get full text

Patterns, costs and cost-effectiveness of care in a trial of chemotherapy for advanced non-small cell lung cancer by Billingham, L.J, Bathers, S, Burton, A, Bryan, S, Cullen, M.H

“…In a recently published randomised trial of chemotherapy versus palliative care in advanced non-small cell lung cancer (the MIC2 trial), chemotherapy was shown…”
Get full text

A randomised multicentre trial of modified CHOP versus MCOP in patients aged 65 years and over with aggressive non-Hodgkin’s lymphoma by Bessell, E. M., Burton, A., Haynes, A. P., Glaholm, J., Child, J. A., Cullen, M. H., Davies, J. M., Smith, G. M., Ellis, I. O., Jack, A., Jones, E. L.

“…Background: The aim of this study was to determine in a randomised trial whether there is any significant difference in toxicity between modified CHOP and MCOP…”
Get full text

Management of febrile neutropenia: ESMO Clinical Recommendations by Marti, F. Marti, Cullen, M. H., Roila, F.

Get full text

Prognostic factors for patients with advanced seminoma treated with platinum-based chemotherapy by Fosså, S.D., Oliver, R.T.D., Stenning, S.P., Horwich, A., Wilkinson, P., Read, G., Mead, G.M., Roberts, J.T., Rustin, G., Cullen, M.H., Kaye, S.B., Harland, S.J., Cook, P.

“…Prognostic factors for 3-year progression-free survival (PFS) were defined in 286 patients with advanced seminoma treated with cisplatin-based chemotherapy at…”
Get full text

The North Atlantic Oscillation: Past, Present, and Future by Visbeck, Martin H., Hurrell, James W., Polvani, Lorenzo, Cullen, Heidi M.

“…The climate of the Atlantic sector exhibits considerable variability on a wide range of time scales. A substantial portion is associated with the North…”
Get full text

Pharmacokinetic Study of Single Doses of Oral Fludarabine Phosphate in Patients With “Low-Grade” Non-Hodgkin's Lymphoma and B-Cell Chronic Lymphocytic Leukemia by FORAN, J. M, OSCIER, D, ORCHARD, J, JOHNSON, S. A, TIGHE, M, CULLEN, M. H, DE TAKATS, P. G, KRAUS, C, KLEIN, M, LISTER, T. A

“…Fludarabine phosphate (F-AMP), a purine analog, requires daily intravenous administration. A pharmacokinetic study of an oral formulation (10 mg…”
Get full text